Drug Search Results
More Filters [+]

NM-003

Alternative Names: nm-003, nm 003, nm003
Latest Update: 2020-12-09
Latest Update Note: News Article

Product Description

Mechanisms of Action: GLP-2 Agonist

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Injection

FDA Designation: Orphan Drug - Graft vs Host Disease *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: 9 Meters Biopharma
Company Location: RALEIGH NC 27615
Company CEO: John Temperato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NM-003

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Graft vs Host Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events